Rating Change
BTIG analysts reiterated a Buy rating on Exagen Inc. (NASDAQ:XGN) on August 05, 2026.
Rating Change BTIG analysts reiterated a Buy rating on Exagen Inc. (NASDAQ:XGN) on August 05, 2026. Market Context Exagen Inc.

BTIG analysts reiterated a Buy rating on Exagen Inc. (NASDAQ:XGN) on August 05, 2026.
Exagen Inc. operates in the Healthcare sector. The stock currently trades at $6.45 with a market capitalization of $163.2M.
Analyst coverage from BTIG provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Exagen Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 05, 2026 | BTIG | Buy | N/A |
| Jun 25, 2026 | Roth Capital | Buy | N/A |
| May 12, 2026 | BTIG | Buy | N/A |
| Apr 20, 2026 | Canaccord Genuity | Buy | N/A |
| Mar 11, 2026 | Craig-Hallum | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View XGN Stock Page
A Buy rating from BTIG reflects the analyst's outlook on Exagen Inc. (NASDAQ:XGN). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the XGN forecast page.
Current market data
NASDAQ · XGN
$7.52
Down: -$0.13 · -1.73%
Live quote updated
Keep reading